Merck Swings To 4Q Loss On Charges; Issues Weak Fiscal-Year View

Published February 9, 2011

Merck Swings To 4Q Loss On Charges; Issues Weak Fiscal-Year View
Merck & Co. (MRK) swung to a fourth-quarter loss as accounting and merger-related charges masked revenue growth, while the year-earlier quarter was significantly boosted by a $ 7.5 billion gain in connection with the former Merck/Schering-Plough partnership.
Read more on FOX Business

Lilly, Bristol Lung Cancer Study Stalls on Clot Risk, Second Trial Ongoing
Eli Lilly & Co. and Bristol-Myers Squibb Co . halted enrollment in one of two late-stage studies of an experimental lung-cancer drug after patients receiving treatment had increased risk of blood clots.
Read more on Bloomberg